Safety profiling of GLP-1 therapy Studies have found that GLP-1 agonists are associated with increased risk of gastrointestinal adverse events spanning from nausea and vomiting to pancreatitis and kidney dysfunction
2 In an interview, Dillon, professor of internal medicine (endocrinology and metabolism) at Carver College of Medicine at the University of Iowa, talked to Targeted Oncology about considerations and potential risks of GLP-1 agents when used in patients with neuroendocrine tumors (NETs) based on current preclinical evidence, as well as current knowledge gaps that warrant future clinical investigation
Chang C-I, Low HP, Qiu L, Strohsnitter WC, Hsieh C-C
Laboratories can use these aligned procurement characteristics to standardize how study arms are documented and repeated
The following adverse events have been discovered to be associated with Ozempic use even though they were not warned about on the Ozempic label: A rare type of blindness caused by impaired blood circulation to the front of the optic nerve
All four are types of semaglutide, which mimics the hormone released by the body when eating food, GLP-1
)
